{"id":33821,"date":"2017-01-26T07:23:44","date_gmt":"2017-01-26T15:23:44","guid":{"rendered":"http:\/\/lifeboat.com\/blog\/2017\/01\/new-drug-transforms-the-immune-system-to-slow-the-progress-of-multiple-sclerosis"},"modified":"2017-06-04T07:53:25","modified_gmt":"2017-06-04T14:53:25","slug":"new-drug-transforms-the-immune-system-to-slow-the-progress-of-multiple-sclerosis","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2017\/01\/new-drug-transforms-the-immune-system-to-slow-the-progress-of-multiple-sclerosis","title":{"rendered":"New Drug Transforms the Immune System to Slow the Progress of Multiple Sclerosis"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/new-drug-transforms-the-immune-system-to-slow-the-progress-of-multiple-sclerosis.jpg\"><\/a><\/p>\n<p>In Brief:<\/p>\n<ul>\n<li>The Multiple Sclerosis Foundation estimates that more than 400,000 people in the United States and about 2.5 million people around the world have MS. <\/li>\n<li>A new drug, Ocrelizumab, is the first known drug shown to work against the primary progressive form of MS by altering the immune system to slow damage to the brain.<\/li>\n<\/ul>\n<p><a href=\"https:\/\/mssociety.ca\/images\/book\/ms-the-facts-you-need.pdf\" target=\"_blank\">Multiple sclerosis<\/a> (MS) is an unpredictable and potentially disabling disease that cripples the central nervous system. It\u2019s a widespread neurological condition that hits young adults, usually between the ages of 20 and 40, caused by an immune system disorder that mistakes a part of the brain as a hostile foreign object and attacks it. Though there are treatments available, particularly for its second state, multiple sclerosis remains incurable.<\/p>\n<p><!-- Link: <a href=\"https:\/\/futurism.com\/new-drug-transforms-the-immune-system-to-slow-the-progress-of-multiple-sclerosis\/\">https:\/\/futurism.com\/new-drug-transforms-the-immune-system-t...sclerosis\/<\/a> --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In Brief: The Multiple Sclerosis Foundation estimates that more than 400,000 people in the United States and about 2.5 million people around the world have MS. A new drug, Ocrelizumab, is the first known drug shown to work against the primary progressive form of MS by altering the immune system to slow damage to the [\u2026]<\/p>\n","protected":false},"author":413,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,47],"tags":[],"class_list":["post-33821","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/33821","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/413"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=33821"}],"version-history":[{"count":2,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/33821\/revisions"}],"predecessor-version":[{"id":59002,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/33821\/revisions\/59002"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=33821"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=33821"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=33821"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}